Healthcare

Top of mind: ASX companies tackling neurological disorders

Highlights:,Several,ASX 200,healthcare stocks are focusing on treatments for neurological disorders.,The neurological drug development landscape is ev...

Assessing Pro Medicus as a Defensive ASX Stock

Assessing Pro Medicus as a Defensive ASX Stock

LTR Pharma Expands into the U.S. Market with Roxus Nasal Spray

LTR Pharma Expands into the U.S. Market with Roxus Nasal Spray

Groundbreaking Advancements: Prescient Therapeutics (ASX:PTX) Launch...

Highlights,Prescient Therapeutics (,ASX:PTX,) has,initiated,a Phase 2a study of PTX-100.,The study will evaluate the efficacy and safety of PTX-100 in...

Orthocell Expands Striate+ Sales into DACH Region Amid Growing Globa...

Highlight:,Striate+ enters Germany, Austria, and Switzerland following strong EU and UK traction,Distribution partner BioHorizons Camlog initiates fir...

Clinuvel's Stroke Treatment Study Shows Promising Results

Highlights,Significant functional improvement observed in stroke trial participants.,Majority show positive radiological outcomes.,Clinuvel (CUV) opti...

Streamlining for Success: 4DMedical Limited (ASX:4DX) Launches Major...

Highlights,Substantial Cost Cuts:,4DMedical Limited (4DX) announces $6.5 million in annual savings.,Financial Resilience:,Despite cost cuts, the compa...

LTR Pharma (ASX:LTP) Expands Horizons with FDA Endorsement and New P...

Highlights,LTR Pharma secures FDA endorsement for SPONTAN® development.,Launch of Roxus® aims to tap into the US personalized healthcare market.,SPONT...

Orthocell Pioneers Expansion with Striate+ in Central Europe

Highlights,Orthocell (OCC) marks its first sales of Striate+ in the DACH region.,Positive clinical outcomes boost the product's market acceptance.,Str...

Expanding Horizons: Orthocell’s Striate+ Makes Groundbreaking Entry...

Highlights,Orthocell (ASX: OCC) ventures into Germany, Austria, and Switzerland with Striate+.,Significant revenue potential eyed with a targeted mark...

Vanguard's Latest US Market ETF Distribution: Key Dates and Details

Highlights,Final distribution announced for (ASX:VTS) holders.,Key dates from ex-distribution to payment detailed.,Important information on CDI cancel...

ASX Stocks Gaining Attention Amid Market Fluctuations

ASX Stocks Gaining Attention Amid Market Fluctuations

Aroa Biosurgery (ARX) Is Well-Positioned for Business Growth

Aroa Biosurgery (ARX) Is Well-Positioned for Business Growth

Immutep makes progress with first lung cancer patient dosing

Immutep makes progress with first lung cancer patient dosing

Immutep Limited (ASX:IMM) Launches Major Phase III Trial Targeting L...

Highlights,Immutep Limited (IMM) begins pivotal Phase III trial for lung cancer treatment.,The global study aims to enroll over 750 patients in 25+ co...

Is Investing in Ramsay Health Care (RHC) Considered Risky?

Is Investing in Ramsay Health Care (RHC) Considered Risky?

Beamtree Expands Automation in Clinical Coding

Beamtree Expands Automation in Clinical Coding

Opthea's Phase 3 trial results fall short in aiding patients, puttin...

Opthea's Phase 3 trial results fall short in aiding patients, putting the company's future in jeopardy.

Clinical Trials and Technological Innovations: A Mixed Landscape

Highlights,Opthea's eye disease trial fails to meet primary endpoints, casting doubts on its future.,HitIQ partners with a major Australian amateur le...

Opthea Seeks Lifeline After Clinical Setback, Suspends Trading to Re...

Highlights,Opthea pauses trading as it explores funding options,Clinical trial for OPT-302 misses key target,Future of wet-AMD treatment strategy unde...